摘要
目的:评价消胀方联合拉米夫定治疗乙型肝炎肝硬化失代偿期患者的临床疗效。方法:76例乙型肝炎肝硬化失代偿期患者随机分为治疗组(n=38)与对照组(n=38),两组在拉米夫定抗病毒治疗基础上,治疗组治以消胀方,对照组治以扶正化瘀胶囊,疗程均为12个月。观察并比较治疗前后两组患者的中医证候积分、慢性肝病疾病特异性量表(CLDQ)积分、Child-Pugh分级(CTP评分)、肝功能、HBVDNA(Log值),同时对所有患者进行B超检查,比较其治疗前后门静脉主干(MPV)、脾静脉(SV)的宽度及脾长度和厚度的变化。结果:①治疗后,两组患者中医证候积分、慢性肝病疾病特异性量表积分、Child-Pugh分级(CTP评分)较治疗前均明显降低(P<0.01),且治疗组积分较对照组亦明显减少(P<0.05或P<0.01);②治疗后,两组患者肝功能较治疗前均明显改善(P<0.01),且治疗组较对照组改善更加明显(P<0.05或P<0.01);③治疗后,两组患者HBVDNA(Log值)较治疗前明显降低(P<0.01),且治疗组较对照组降低更加明显(P<0.01);④B超检查结果显示,治疗后治疗组患者MPV、SV的宽度及脾长度、脾厚度均明显减小(P<0.05或P<0.01),而对照组患者仅MPV宽度、脾长度有明显的减小(P<0.01),且治疗后治疗组MPV、SV宽度及脾长度、脾厚度较对照组有明显差异(P<0.05或P<0.01)。结论:消胀方联合拉米夫定能够改善乙型肝炎肝硬化失代偿期患者的肝功能,降低患者的CTP评分,明显降低患者的中医证候量化积分及CLDQ积分,具有较好的临床疗效。
Objective： To evaluate the effects of ＂Xiaozhang Formula＂ combined with lamivudine on chronic hepatitis B patients with cirrhosis in their decompensation period.Methods： Seventy-six cases of chronic hepatitis B patients with cirrhosis in their decompensation period were randomly divided into treatment group（n=38）and control group（n=38）.Based on the antivirus therapy with lamivudine,the treatment group and the control group were treated by ＂Xiaozhang Formula＂ and ＂Fuzheng Huayu Capsule＂ respectively with the course of 12 months.Score of traditional Chinese medicine（TCM） syndrome,score of chronic liver disease-specific questionnaire（CLDQ）,Child-Pugh classification（CTP scores）,liver function and HBVDNA were observed and the width of main portal vein（MPV）and splenic vein（SV）,and thickness and length of spleen were examined by B-type ultrasonography.Results： ①After treatment,the scores of TCM syndrome,CLDQ scores and CTP scores of the two groups were significantly decreased（P0.01）,and the scores of treatment group were lower than those of control group（P0.05 or P0.01）.②After treatment,the liver function of the two groups was obviously improved（P0.01）,and the treatment group improved more obviously compared with control group（P0.05 or P0.01）.③After treatment,the levels of HBVDNA of two groups were remarkably reduced（P0.01）,and the treatment group decreased more obviously than control group（P0.01）.④After treatment,the width of MPV and SV and the thickness and length of spleen were significantly reduced in treatment group（P0.05 or P0.01）,and the width of MPV and length of spleen were reduced in control group（P0.01）,and there were statistical differences between treatment group and control group in the width of MPV and SV and the thickness and length of spleen（P0.05 or P0.01）.Conclusion： ＂Xiaozhang Formula＂ combined with lamivudine can improve the liver function of chronic hepatitis B patients with cirrhosis in their decompensa
出处
《上海中医药大学学报》
CAS
2011年第1期32-35,共4页
Academic Journal of Shanghai University of Traditional Chinese Medicine
基金
国家"十一五"科技支撑计划资助项目(2006BAI08B02-04)
上海市教育委员会重点学科(第5期)建设资助项目(J50307)
关键词
消胀方
拉米夫定
乙型肝炎
肝硬化
失代偿期
＂Xiaozhang Formula＂
lamivudine
chronic hepatitis B
cirrhosis
decompensation period
